UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | SEC 1473 (7-02) | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option | 10/17/2006 | 10/17/2016 | Common Stock | 3,727 (1) (2) (6) | $ 0.25 | D | |
Stock Option | 04/27/2007 | 04/27/2017 | Common Stock | 1,028 (1) (2) (6) | $ 0.25 | D | |
Stock Option | 12/06/2007 | 12/06/2017 | Common Stock | 601 (1) (3) (6) | $ 0.25 | D | |
Stock Option | 11/18/2008 | 11/18/2018 | Common Stock | 309 (1) (4) (6) | $ 0.25 | D | |
Stock Option | 06/20/2011 | 06/20/2021 | Common Stock | 16,829 (1) (5) (6) | $ 1 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Friedman Mark Louis C/O AXOGEN, INC. 13859 PROGRESS BOULEVARD, SUITE 100 ALACHUA, FL 32615 |
See Remarks |
/s/ Mark Friedman | 10/11/2011 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | Pursuant to an Agreement and Plan of Merger, dated as of May 31, 2011, by and among LecTec Corporation ("LecTec"), Nerve Merger Sub Corp., a subsidiary of LecTec ("Merger Sub"), and AxoGen Corporation ("AC"), which the parties amended on June 30, 2011 and August 9, 2011 (as amended, the "Merger Agreement"), Merger Sub merged with and into AC, with AC continuing after the merger as the surviving corporation and a wholly owned subsidiary of LecTec (the "Merger"). The Merger was completed on September 30, 2011, and LecTec was renamed AxoGen, Inc. ("AxoGen"). In connection with the Merger, each option to purchase shares of AC common stock was converted to an option to purchase 0.03727336 of a share of AxoGen common stock. |
(2) | 100% of the options have vested. |
(3) | 526 options have vested, and 75 options are unvested. |
(4) | 193 options have vested, and 116 options are unvested. |
(5) | None of the options have vested. |
(6) | These options vest semi-annually over four years from the date of grant. |
Remarks: Vice President of Regulatory Affairs and Quality Assurance of AxoGen Corporation, a wholly owned subsidiary of Autogen, Inc. |